INDIVIOR PLC (INVVY)

2.83
0.07 2.54
OTC
Prev Close 2.76
Open 2.74
Day Low/High 2.68 / 2.83
52 Wk Low/High 1.98 / 33.83
Volume 43.05K
Exchange OTC
Shares Outstanding 728.77B
Market Cap 1.01B
Div & Yield N.A. (N.A)

Latest News

Hagens Berman Alerts Indivior PLC (INVVY) Investors Of The Firm's Investigation Of Possible Securities Law Violations

Hagens Berman Alerts Indivior PLC (INVVY) Investors Of The Firm's Investigation Of Possible Securities Law Violations

SAN FRANCISCO, April 11, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Indivior PLC (OTC: INVVY) to the firm's investigation of possible Federal securities law violations.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Indivior PLC - INVVY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Indivior PLC - INVVY

NEW YORK, April 10, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Indivior PLC ("Indivior" or the "Company") (OTCMKTS: INVVY).

LOST MONEY IN INDIVIOR PLC? Gibbs Law Group Investigates Potential Securities Claims In The Wake Of Justice Department Indictment

LOST MONEY IN INDIVIOR PLC? Gibbs Law Group Investigates Potential Securities Claims In The Wake Of Justice Department Indictment

Gibbs Law Group is investigating claims on behalf of investors of Indivior PLC (OTC: INVVY) involving possible securities law violations following news that the US Justice Department filed a lawsuit against Indivior for illegal marketing.

Indivior Plummets on Charges of 'Illicit Nationwide Scheme'

Indivior Plummets on Charges of 'Illicit Nationwide Scheme'

U.K. drugmaker balks at Justice Department claims it misled health care providers to push its treatment for opioid addiction.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Indivior PLC - INVVY

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Indivior PLC - INVVY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Indivior PLC (OTC: INVVY) resulting from allegations that Indivior may have issued materially misleading business...

Statement Of Indivior On Grand Jury Indictment

Statement Of Indivior On Grand Jury Indictment

Company Believes U.S. Justice Department Is Fundamentally Wrong, Will Contest Charges Vigorously

Indivior Announces New Study Data In Patients With Moderate To Severe Opioid Use Disorder (OUD) At The 50th ASAM Annual Conference

Indivior Announces New Study Data In Patients With Moderate To Severe Opioid Use Disorder (OUD) At The 50th ASAM Annual Conference

Injecting opioid users may benefit from higher maintenance dose of SUBLOCADE™ (buprenorphine extended-release), a once-monthly injection for the treatment of moderate to severe opioid use disorder

The Journal Of Addiction Medicine Publishes Patient-centered Outcomes From The Phase 3 Study Of SUBLOCADE™ (Buprenorphine Extended-Release) Injection In Patients With Moderate To Severe Opioid Use Disorder (OUD)

The Journal Of Addiction Medicine Publishes Patient-centered Outcomes From The Phase 3 Study Of SUBLOCADE™ (Buprenorphine Extended-Release) Injection In Patients With Moderate To Severe Opioid Use Disorder (OUD)

Six monthly injections of SUBLOCADE™ improved patient health status and health-related quality of life compared to placebo in 24-week pivotal trial

Indivior Announces Launch Of PERSERIS™ (risperidone) For The Treatment Of Schizophrenia In Adults

Indivior Announces Launch Of PERSERIS™ (risperidone) For The Treatment Of Schizophrenia In Adults

PERSERIS is the only subcutaneous risperidone-containing long-acting injectable available in the United States

The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety And Tolerability Of SUBLOCADE™ (Buprenorphine Extended-Release) Injection For Subcutaneous Use (CIII) In Patients With Moderate To Severe Opioid Use Disorder (OUD)

The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety And Tolerability Of SUBLOCADE™ (Buprenorphine Extended-Release) Injection For Subcutaneous Use (CIII) In Patients With Moderate To Severe Opioid Use Disorder (OUD)

SUBLOCADE - the first FDA-approved monthly injectable buprenorphine treatment for OUD - met primary and key secondary endpoints in the 24-week pivotal trial

DURECT Corporation Provides Corporate Update

DURECT Corporation Provides Corporate Update

Live Webcast Today at 8:00 a.m. Eastern Time

Indivior Publishes Design And Patient Characteristics For Real-World Study Of Life Changes In People Treated With SUBLOCADE™ (Buprenorphine Extended-Release) In Contemporary Clinical Trials

Indivior Publishes Design And Patient Characteristics For Real-World Study Of Life Changes In People Treated With SUBLOCADE™ (Buprenorphine Extended-Release) In Contemporary Clinical Trials

RECOVER study designed to understand the long-term clinical, environmental and socio-economic outcomes of SUBLOCADE treated individuals

Aquestive Therapeutics Provides End Of Year Business Update, Including Progress Of Its Proprietary CNS Assets, Financial And Legal Matters

Aquestive Therapeutics Provides End Of Year Business Update, Including Progress Of Its Proprietary CNS Assets, Financial And Legal Matters

- Projects full year 2018 revenues over $67 million, exceeding expectations, and projects end-of-year cash and cash equivalents in the range of $58 million to $60 million

Commercial Launch Plans Announced For PERSERIS™ (risperidone) Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults

Commercial Launch Plans Announced For PERSERIS™ (risperidone) Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults

Indivior PLC Announces Plan for Commercial Launch in February 2019 with 50 Sales Representatives

Court Of Appeals For The Federal Circuit Declines To Immediately Issue Mandate After Preliminary Injunction Ruling

Court Of Appeals For The Federal Circuit Declines To Immediately Issue Mandate After Preliminary Injunction Ruling

SLOUGH, England, Dec. 12, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.

Indivior To Host Conference Call On December 18th; Previously-Scheduled Capital Markets Day To Be Held In February 2019

Indivior To Host Conference Call On December 18th; Previously-Scheduled Capital Markets Day To Be Held In February 2019

SLOUGH, England, Nov. 27, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that in light of the recent decision by the Court of Appeals for the Federal Circuit (CAFC) vacating the preliminary injunction against...

Indivior Announces Health Canada Approval Of SUBLOCADETM (Buprenorphine Extended-Release) Injection For Patients With Moderate To Severe Opioid Use Disorder

Indivior Announces Health Canada Approval Of SUBLOCADETM (Buprenorphine Extended-Release) Injection For Patients With Moderate To Severe Opioid Use Disorder

SUBLOCADE is the first and only once-monthly injectable buprenorphine formulation approved in Canada for the management of moderate to severe opioid use disorder SLOUGH, England and RICHMOND, Va.

Court Of Appeals For The Federal Circuit Lifts Preliminary Injunction On Generic (buprenorphine And Naloxone) Sublingual Film

Court Of Appeals For The Federal Circuit Lifts Preliminary Injunction On Generic (buprenorphine And Naloxone) Sublingual Film

-Company will continue to defend its intellectual property and implement contingency plan­

PERSERIS™, The First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available In The U.S. For The Treatment Of Schizophrenia In Adults

PERSERIS™, The First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available In The U.S. For The Treatment Of Schizophrenia In Adults

PERSERIS delivers risperidone in a new once-monthly extended-release delivery system. Neither a loading dose nor any supplemental oral risperidone is recommended.

Indivior Announces Upcoming Investor Events

Indivior Announces Upcoming Investor Events

SLOUGH, United Kingdom and RICHMOND, Va., Nov.

Indivior Announces Nine Month And Third Quarter 2018 Results

Indivior Announces Nine Month And Third Quarter 2018 Results

SLOUGH, United Kingdom and RICHMOND, Va., Nov.

Indivior Applauds Enactment Of The SUPPORT For Patients And Communities Act Of 2018

Indivior Applauds Enactment Of The SUPPORT For Patients And Communities Act Of 2018

Act Broadens Access to Medication-Assisted Treatment for People Affected by Opioid Addiction

The 6 Medications Being Used to Tackle the Opioid Epidemic

The 6 Medications Being Used to Tackle the Opioid Epidemic

The U.S. opioid crisis rages on. TheStreet takes a look at several drugs being used to help treat people.

Indivior Shares Plunge Amid Generics Threat to Suboxone Opioid Treatment

Indivior Shares Plunge Amid Generics Threat to Suboxone Opioid Treatment

The FTSE 250 pharmaceutical company said the U.S. District Court in Delaware has found that claims of a proposed generic version of Indivior's opioid addiction treatment by Dr. Reddy's does not infringe patents.